

IN THE CLAIMS

1 1.-21.(Cancelled)

1 22. (Previously Presented) Antibodies raised against fragments of apo B100 comprising a variable heavy region

2 (V_H) selected from the group of nucleic acid sequences consisting of

3 (SEQ. ID. NO. 1)

4 (SEQ. ID. NO. 3)

5 (SEQ. ID. NO. 5)

6 (SEQ. ID. NO. 7)

7 (SEQ. ID. NO. 9)

8 (SEQ. ID. NO. 11)

9 (SEQ. ID. NO. 19)

10 (SEQ. ID. NO. 21)

11 (SEQ. ID. NO. 23)

12 (SEQ. ID. NO. 25)

13 (SEQ. ID. NO. 27)

14 (SEQ. ID. NO. 29)

15 (SEQ. ID. NO. 31)

16 (SEQ. ID. NO. 33)

17 (SEQ. ID. NO. 35)

18 (SEQ. ID. NO. 37)

19 in combination with a variable light region (V_L) selected from the group of nucleic acid sequences consisting of

20 (SEQ. ID. NO. 2)

21 (SEQ. ID. NO. 4)

22 (SEQ. ID. NO. 6)

23 (SEQ. ID. NO. 8)

24 (SEQ. ID. NO. 10)

25 (SEQ. ID. NO. 12)

26 (SEQ. ID. NO. 20)

27 (SEQ. ID. NO. 22)

28 (SEQ. ID. NO. 24)

29 (SEQ. ID. NO. 26)

30 (SEQ. ID. NO. 28)

31 (SEQ. ID. NO. 30)

32 (SEQ. ID. NO. 32)

33 (SEQ. ID. NO. 34)

34 (SEQ. ID. NO. 36)

35 (SEQ. ID. NO. 38)

1 23. (Previously Presented) Antibody according to claim 22, wherein the antibody is characterized in that it
2 comprises the variable heavy region(V_H)

3 (SEQ ID NO: 1)

4 and the variable light region (V_L)

5 (SEQ ID NO: 2)

1 24. (Previously Presented) Antibody according to claim 22, wherein the antibody is characterized in that it
2 comprises

3 the variable heavy region (V_H)

4 (SEQ ID NO: 3)

5 and the variable light region (V_L)

6 (SEQ ID NO: 4)

1 25. (Previously Presented) Antibody according to claim 22, wherein the antibody is characterized in that it
2 comprises

3 the variable heavy region (V_H)

4 (SEQ ID NO: 5)

5 and the variable light region (V_L)

6 (SEQ ID NO: 6)

1 26. (Previously Presented) Antibody according to claim 22, wherein the antibody is characterized in that it
2 comprises the variable heavy region (V_H)

3 (SEQ ID NO: 7)

4 and the variable light region (V_L)

5 (SEQ ID NO: 8)

1 27. (Previously Presented) Antibody according to claim 22, wherein the antibody is characterized in that it
2 comprises

3 the variable heavy region (V_H)

4 (SEQ ID NO: 9)

5 and the variable light region (V_L)
6 (SEQ ID NO: 10)

1 28. (Previously Presented) Antibody according to claim 22, wherein the antibody is characterized in that it
2 comprises

3 the variable heavy region (V_H)

4 (SEQ ID NO: 11)

5 and the variable light region (V_L)

6

7 (SEQ ID NO: 12)

1 29-50. (Cancelled)

1 51. (Previously Presented) Pharmaceutical composition comprising an isolated human antibody directed
2 towards at least one oxidized fragment of apolipoprotein B for therapeutical or prophylactical treatment of
3 atherosclerosis by means of passive immunization, which antibody is present in combination with a
4 pharmaceutical excipient.

1 52. (Previously Presented) Antibody according to claim 34, wherein the antibody is characterized in that it
2 comprises the variable heavy region (V_H)
3 (SEQ. ID. NO. 27).

1 53. (Previously Presented) Antibody according to claim 34, wherein the antibody is characterized in that it
2 comprises the variable light region (V_L)
3 (SEQ. ID. NO. 28).

1 54. (Previously Presented) Antibody according to claims 1-2, wherein the antibody is characterized in that it
2 has been raised from the apoB100 derived sequence (SEQ. ID. NO. 70).

1 55. (Previously Presented) Antibody according to claims 54, wherein the antibody is characterized in that it
2 comprises the variable heavy region (V_H)
3 (SEQ. ID. NO. 27)
4 and the variable light region (V_L)
5 (SEQ. ID. NO. 28).

1 56. (New) Antibody according to claim 22 wherein the heavy variable region (V_H) comprises (SEQ. ID. NO.
2 27) in combination with a light variable region consisting of (SEQ. ID. NO. 28) in combination with an
3 oxidized fragment consisting of (SEQ. ID. NO. 70).